Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2017 · 10-Q
Revenue$80.40M$80.40M+41.5% vs Q3 2016 Net Income$15.96M$15.96M−74.2% vs Q3 2016 EPS Diluted$0.29$0.29−75.4% vs Q3 2016 Operating Income$22,342,000+12.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$38,584,000+38.6% Margins · derivedOperating margin27.8%−7.1 pt vs Q3 2016
Net margin19.9%−89.0 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end